摘要
盐皮质激素受体阻滞剂是治疗慢性心力衰竭的基石药物,但甾体类盐皮质激素受体阻滞剂如螺内酯、依普利酮等却因可能引起高钾血症、肾功能下降等不良反应在临床上的使用受到了限制。新型的非甾体类盐皮质激素受体阻滞剂非奈利酮具有较高的耐受性和选择性,在保证了治疗有效性的同时,具有更好的安全性。现对非奈利酮治疗慢性心力衰竭的研究进展做一综述。
Mineralocorticoid receptor antagonists are very important for the treatment of chronic heart failure,however,because of serious side effects such as hyperkalemia and decreased renal function,steroidal mineralocorticoid receptor antagonists like spironolactone and eplerenone may be limited.The new non-steroidal mineralocorticoid receptor antagonist Finerenone possesses high tolerance and selectivity,which could ensure the effectiveness of treatment with excellent safety.This article reviews the progress of Finerenone in the treatment of chronic heart failure.
作者
郭曦滢
孙煌
樊朝美
张健
GUO Xiying;SUN Huang;FAN Chaomei;ZHANG Jian(Department of Cardiology,The First Affiliated Hospital of Kunming Medical University,Kunming 653000,Yunnan,China;Chinese Academy of Medical Sciences,Beijing Fuwai Hospital,Beijing 100037,China)
出处
《心血管病学进展》
CAS
2020年第10期1021-1025,共5页
Advances in Cardiovascular Diseases
基金
昆明医科大学第一附属医院博士科研基金(2017BS019)。
